{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T18:51:08Z","timestamp":1794336668862,"version":"4.9.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"vor","delay-in-days":28,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["92374202, 32441099, 32141004, 82271835, 82071813, 81671602, 82171772, 82202003 and U1903210"],"award-info":[{"award-number":["92374202, 32441099, 32141004, 82271835, 82071813, 81671602, 82171772, 82202003 and U1903210"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005090","name":"Beijing Nova Program","doi-asserted-by":"publisher","award":["20220484206"],"award-info":[{"award-number":["20220484206"]}],"id":[{"id":"10.13039\/501100005090","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-68100-w","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T09:38:00Z","timestamp":1767778680000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy and safety of low-dose interleukin 2 for Beh\u00e7et\u2019s syndrome: a randomized, placebo-controlled, double-blind, phase 2 clinical trial"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1691-8372","authenticated-orcid":false,"given":"Tian","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4541-6603","authenticated-orcid":false,"given":"Wenyan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiyi","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiali","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiling","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2814-851X","authenticated-orcid":false,"given":"Yuan","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuebo","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2368-812X","authenticated-orcid":false,"given":"Xue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7448-8884","authenticated-orcid":false,"given":"Yunshan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ru","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuewu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huixin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6385-8958","authenticated-orcid":false,"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanlei","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianping","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9709-1532","authenticated-orcid":false,"given":"Xiaolin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3904-8928","authenticated-orcid":false,"given":"Jing","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanguo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,7]]},"reference":[{"key":"68100_CR1","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMra2305712","volume":"390","author":"D Saadoun","year":"2024","unstructured":"Saadoun, D., Bodaghi, B. & &Cacoub, P. Beh\u00e7et\u2019s syndrome. N. Engl. J.Med. 390, 640\u2013651 (2024).","journal-title":"N. Engl. J.Med."},{"key":"68100_CR2","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/S0140-6736(23)02629-6","volume":"403","author":"G Emmi","year":"2024","unstructured":"Emmi, G. et al. Beh\u00e7et\u2019s syndrome. Lancet 403, 1093\u20131108 (2024).","journal-title":"Lancet"},{"key":"68100_CR3","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/nrrheum.2018.3","volume":"14","author":"H Yazici","year":"2018","unstructured":"Yazici, H. et al. Beh\u00e7et syndrome: a contemporary view. Nat. Rev. Rheumatol. 14, 119 (2018).","journal-title":"Nat. Rev. Rheumatol."},{"key":"68100_CR4","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s41572-021-00301-1","volume":"7","author":"Y Yazici","year":"2021","unstructured":"Yazici, Y. et al. Beh\u00e7et syndrome. Nat. Rev. Dis. Primers. 7, 67 (2021).","journal-title":"Nat. Rev. Dis. Primers."},{"key":"68100_CR5","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1136\/annrheumdis-2018-213225","volume":"77","author":"G Hatemi","year":"2018","unstructured":"Hatemi, G. et al. 2018 update of the EULAR recommendations for the management of Beh\u00e7et\u2019s syndrome. Ann. Rheum. Dis. 77, 808\u2013818 (2018).","journal-title":"Ann. Rheum. Dis."},{"key":"68100_CR6","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/j.semarthrit.2018.05.008","volume":"48","author":"P Leccese","year":"2019","unstructured":"Leccese, P. et al. Management of skin, mucosa and joint involvement of Beh\u00e7et\u2019s syndrome: a systematic review for update of the EULAR recommendations for the management of Beh\u00e7et\u2019s syndrome. Semin. Arthritis. Rheum. 48, 752\u2013762 (2019).","journal-title":"Semin. Arthritis. Rheum."},{"key":"68100_CR7","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s11926-021-01011-z","volume":"23","author":"F Alibaz-Oner","year":"2021","unstructured":"Alibaz-Oner, F. & Direskeneli, H. Advances in the treatment of Behcet\u2019s disease. Curr. Rheumatol. Rep. 23, 47 (2021).","journal-title":"Curr. Rheumatol. Rep."},{"key":"68100_CR8","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1056\/NEJMoa1408684","volume":"372","author":"G Hatemi","year":"2015","unstructured":"Hatemi, G. et al. Apremilast for Beh\u00e7et\u2019s syndrome-a phase 2, placebo-controlled study. N. Engl. J. Med. 372, 1510\u20131528 (2015).","journal-title":"N. Engl. J. Med."},{"key":"68100_CR9","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1056\/NEJMoa1816594","volume":"381","author":"G Hatemi","year":"2019","unstructured":"Hatemi, G. et al. Trial of apremilast for oral ulcers in Beh\u00e7et\u2019s syndrome. N. Engl. J. Med. 381, 1918\u20131928 (2019).","journal-title":"N. Engl. J. Med."},{"key":"68100_CR10","doi-asserted-by":"publisher","first-page":"80","DOI":"10.55563\/clinexprheumatol\/ra8ize","volume":"132","author":"G Hatemi","year":"2021","unstructured":"Hatemi, G. et al. Apremilast for oral ulcers associated with active Beh\u00e7et\u2019s syndrome over 68 weeks: long-term results from a phase 3 randomised clinical trial. Clin. Exp. Rheumatol. 132, 80\u201387 (2021).","journal-title":"Clin. Exp. Rheumatol."},{"key":"68100_CR11","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1136\/annrheumdis-2019-215437","volume":"78","author":"G Lopalco","year":"2021","unstructured":"Lopalco, G. et al. Real-world effectiveness of apremilast in multirefractory mucosal involvement of Beh\u00e7et\u2019s disease. Ann. Rheum. Dis. 78, 1736\u20131737 (2021).","journal-title":"Ann. Rheum. Dis."},{"key":"68100_CR12","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1093\/mr\/roab008","volume":"32","author":"M Takeno","year":"2022","unstructured":"Takeno, M. et al. Apremilast in a Japanese subgroup with Beh\u00e7et\u2019s syndrome: results from a Phase 3, randomised, double-blind, placebo-controlled study. Mod. Rheumatol. 32, 413\u2013421 (2022).","journal-title":"Mod. Rheumatol."},{"key":"68100_CR13","first-page":"283","volume":"15","author":"D Klatzmann","year":"2015","unstructured":"Klatzmann, D. & Abbas, A. K. The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases. Nat. Rev. Rheumatol. 15, 283\u2013294 (2015).","journal-title":"Nat. Rev. Rheumatol."},{"key":"68100_CR14","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/s41590-018-0120-4","volume":"19","author":"M Dominguez-Villar","year":"2018","unstructured":"Dominguez-Villar, M. & Hafler, D. A. Regulatory T cells in autoimmune disease. Nat. Immunol. 19, 665\u2013673 (2018).","journal-title":"Nat. Immunol."},{"key":"68100_CR15","first-page":"180","volume":"12","author":"O Boyman","year":"2012","unstructured":"Boyman, O. & Sprent, J. The role of interleukin-2 during homeostasis and activation of the immune system. Nat. Rev. Rheumatol. 12, 180\u2013190 (2012).","journal-title":"Nat. Rev. Rheumatol."},{"key":"68100_CR16","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.immuni.2013.01.004","volume":"38","author":"W Liao","year":"2013","unstructured":"Liao, W., Lin, J. X. & Leonard, W. J. Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity 38, 13\u201325 (2013).","journal-title":"Immunity"},{"key":"68100_CR17","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/nm.4148","volume":"22","author":"J He","year":"2016","unstructured":"He, J. et al. Low-dose interleukin-2 treatment selectively modulates CD4(+) T cell subsets in patients with systemic lupus erythematosus. Nat. Med. 22, 991\u2013993 (2016).","journal-title":"Nat. Med."},{"key":"68100_CR18","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s41392-022-00887-2","volume":"7","author":"X Zhang","year":"2022","unstructured":"Zhang, X. et al. Efficacy and safety of low-dose interleukin-2 in combination with methotrexate in patients with active rheumatoid arthritis: a randomized, double-blind, placebo-controlled phase 2 trial. Signal Transduct. Target Ther. 7, 67 (2022).","journal-title":"Signal Transduct. Target Ther."},{"key":"68100_CR19","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1136\/annrheumdis-2018-214229","volume":"78","author":"M Rosenzwajg","year":"2019","unstructured":"Rosenzwajg, M. et al. Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial. Ann. Rheum. Dis. 78, 209\u2013217 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"68100_CR20","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1002\/rai2.12148","volume":"4","author":"J Cheng","year":"2024","unstructured":"Cheng, J. et al. Low-dose interleukin-2 for the treatment of systemic lupus erythematosus with recurrent rash. Rheumatol. Autoimmun. 4, 265\u2013266 (2024).","journal-title":"Rheumatol. Autoimmun."},{"key":"68100_CR21","doi-asserted-by":"publisher","first-page":"746","DOI":"10.55563\/clinexprheumatol\/lnn76t","volume":"39","author":"X Liu","year":"2021","unstructured":"Liu, X. et al. Low-dose IL-2 effectively restored decreased regulatory T cells in patients with Beh\u00e7et\u2019s disease. Clin. Exp. Rheumatol. 39, 746\u2013752 (2021).","journal-title":"Clin. Exp. Rheumatol."},{"key":"68100_CR22","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.jaci.2011.05.029","volume":"128","author":"G Geri","year":"2011","unstructured":"Geri, G. et al. Critical role of IL-21 in modulating TH17 and regulatory T cells in Beh\u00e7et disease. J. Allergy. Clin. Immunol. 128, 655\u2013664 (2011).","journal-title":"J. Allergy. Clin. Immunol."},{"key":"68100_CR23","doi-asserted-by":"publisher","first-page":"e31173","DOI":"10.1097\/MD.0000000000031173","volume":"101","author":"W Zhou","year":"2011","unstructured":"Zhou, W. et al. Refractory Beh\u00e7et\u2019s disease treated with low-dose interleukin-2: a case report. Medicine 101, e31173 (2011).","journal-title":"Medicine"},{"key":"68100_CR24","doi-asserted-by":"publisher","first-page":"103172","DOI":"10.1016\/j.jaut.2024.103172","volume":"144","author":"R Lorenzon","year":"2024","unstructured":"Lorenzon, R. et al. The universal effects of low-dose interleukin-2 across 13 autoimmune diseases in a basket clinical trial. J. Autoimmun. 144, 103172 (2024).","journal-title":"J. Autoimmun."},{"key":"68100_CR25","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.3389\/fimmu.2019.02830","volume":"10","author":"A Bettiol","year":"2019","unstructured":"Bettiol, A. et al. Treating the different phenotypes of Beh\u00e7et\u2019s syndrome. Front. Immunol. 10, 2830 (2019).","journal-title":"Front. Immunol."},{"key":"68100_CR26","first-page":"49","volume":"23","author":"Y Soejima","year":"2021","unstructured":"Soejima, Y. et al. Changes in the proportion of clinical clusters contribute to the phenotypic evolution of Beh\u00e7et\u2019s disease in Japan. Ann. Rheum. Dis. 23, 49 (2021).","journal-title":"Ann. Rheum. Dis."},{"key":"68100_CR27","doi-asserted-by":"publisher","first-page":"2923","DOI":"10.1093\/rheumatology\/keab840","volume":"61","author":"H Zhong","year":"2022","unstructured":"Zhong, H. et al. Efficacy and safety of tocilizumab in Beh\u00e7et\u2019s syndrome with refractory arterial lesions: a single-centre observational cohort study in China. Rheumatology 61, 2923\u20132930 (2022).","journal-title":"Rheumatology"},{"key":"68100_CR28","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1056\/NEJMoa1108188","volume":"365","author":"J Koreth","year":"2011","unstructured":"Koreth, J. et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N. Engl. J. Med. 365, 2055\u20132066 (2011).","journal-title":"N. Engl. J. Med."},{"key":"68100_CR29","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1056\/NEJMoa1105143","volume":"365","author":"D Saadoun","year":"2011","unstructured":"Saadoun, D. et al. Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N. Engl. J. Med. 365, 2067\u20132077 (2011).","journal-title":"N. Engl. J. Med."},{"key":"68100_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2023.109247","volume":"247","author":"JQ Wang","year":"2023","unstructured":"Wang, J. Q. et al. Consecutive injections of low-dose interleukin-2 improve symptoms and disease control in patients with chronic spontaneous urticaria. Clin. Immunol. 247, 109247 (2023).","journal-title":"Clin. Immunol."},{"key":"68100_CR31","doi-asserted-by":"publisher","first-page":"e2241451","DOI":"10.1001\/jamanetworkopen.2022.41451","volume":"5","author":"J He","year":"2022","unstructured":"He, J. et al. Efficacy and safety of low-dose interleukin 2 for primary Sj\u00f6gren syndrome: a randomized clinical trial. JAMA Netw. Open 5, e2241451 (2022).","journal-title":"JAMA Netw. Open"},{"key":"68100_CR32","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S2213-8587(13)70113-X","volume":"1","author":"A Hartemann","year":"2022","unstructured":"Hartemann, A. et al. Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1\/2 randomised, double-blind, placebo-controlled trial. Lancet. Diabetes Endocrinol. 1, 295\u2013305 (2022).","journal-title":"Lancet. Diabetes Endocrinol."},{"key":"68100_CR33","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1136\/annrheumdis-2019-215396","volume":"79","author":"J He","year":"2022","unstructured":"He, J. et al. Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial. Ann. Rheum. Dis. 79, 141\u2013149 (2022).","journal-title":"Ann. Rheum. Dis."},{"key":"68100_CR34","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1136\/annrheumdis-2018-213036","volume":"77","author":"M Miao","year":"2018","unstructured":"Miao, M. et al. Short-term and low-dose IL-2 therapy restores the Th17\/Treg balance in the peripheral blood of patients with primary Sj\u00f6gren\u2019s syndrome. Ann. Rheum. Dis. 77, 1838\u20131840 (2018).","journal-title":"Ann. Rheum. Dis."},{"key":"68100_CR35","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1007\/s40744-021-00301-3","volume":"8","author":"M Miao","year":"2021","unstructured":"Miao, M. et al. Treatment of active idiopathic inflammatory myopathies by low-dose interleukin-2: a prospective cohort pilot study. Rheumatol. Ther. 8, 835\u2013847 (2021).","journal-title":"Rheumatol. Ther."},{"key":"68100_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.757099","volume":"12","author":"Y Zhufeng","year":"2022","unstructured":"Zhufeng, Y. et al. Modification of intestinal microbiota dysbiosis by low-dose interleukin-2 in dermatomyositis: a post hoc analysis from a clinical trial study. Front. Cell Infect.Microbiol. 12, 757099 (2022).","journal-title":"Front. Cell Infect.Microbiol."},{"key":"68100_CR37","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/s41584-021-00707-x","volume":"17","author":"AGA Kolios","year":"2021","unstructured":"Kolios, A. G. A. et al. Interleukin-2 and regulatoryT cells in rheumatic diseases. Nat. Rev. Rheumatol. 17, 749\u2013766 (2021).","journal-title":"Nat. Rev. Rheumatol."},{"key":"68100_CR38","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.159406","volume":"7","author":"N Tchitchek","year":"2022","unstructured":"Tchitchek, N. et al. Low-dose IL-2 shapes a tolerogenic gut microbiota that improves autoimmunity and gut inflammation. JCI Insight 7, e159406 (2022).","journal-title":"JCI Insight"},{"key":"68100_CR39","first-page":"1078","volume":"335","author":"International Study Group for Beh\u00e7et\u2019s Disease.","year":"1990","unstructured":"International Study Group for Beh\u00e7et\u2019s Disease. Criteria for diagnosis of Beh\u00e7et\u2019s disease. Lancet 335, 1078\u20131080 (1990).","journal-title":"Lancet"},{"key":"68100_CR40","first-page":"77","volume":"31","author":"S Yilmaz","year":"2013","unstructured":"Yilmaz, S. et al. Patient-driven assessment of disease activity in Beh\u00e7et\u2019s syndrome: cross-cultural adaptation, reliability and validity of the Turkish version of the Beh\u00e7et\u2019s syndrome activity score. Clin. Exp. Rheumatol. 31, 77\u201383 (2013).","journal-title":"Clin. Exp. Rheumatol."},{"key":"68100_CR41","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1002\/acr.24511","volume":"74","author":"G Hatemi","year":"2022","unstructured":"Hatemi, G. et al. Core set of domains for outcome measures in Beh\u00e7et\u2019s syndrome. Arthritis. Care Res. 74, 691\u2013699 (2022).","journal-title":"Arthritis. Care Res."},{"key":"68100_CR42","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1093\/rheumatology\/38.8.728","volume":"38","author":"BB Bhakta","year":"1999","unstructured":"Bhakta, B. B. et al. Beh\u00e7et\u2019s disease: evaluation of a new instrument to measure clinical activity. Rheumatology 38, 728\u2013733 (1999).","journal-title":"Rheumatology"},{"key":"68100_CR43","first-page":"931","volume":"31","author":"G Gilworth","year":"2014","unstructured":"Gilworth, G. et al. Development of the BD-QoL: a quality of life measure specific to Beh\u00e7et\u2019s disease. J. Rheumatol. 31, 931\u2013937 (2014).","journal-title":"J. Rheumatol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-68100-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-68100-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-68100-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T16:04:42Z","timestamp":1770221082000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-68100-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,7]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["68100"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-68100-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5416266\/v1","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,7]]},"assertion":[{"value":"11 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1344"}}